iQSTEL Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that iQSTEL Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.90M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $283.22M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $144.50M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $93.20M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $64.70M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $44.91M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $18.03M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $13.78M | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $9.62M | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | $7.51M | Apr 10, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.46M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $8.27M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $4.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.79M | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $1.53M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $962.4K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $780.9K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.19M | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $870.9K | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | $618.0K | Apr 10, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.51M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($5.18M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($763.3K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.97M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.84M) | Apr 14, 2023 |
| FY2022 | Dec 31, 2020 | ($3.84M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($5.46M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.10M) | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | ($291.9K) | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | ($355.7K) | Apr 10, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.25M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($834.1K) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($315.5K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.19M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($2.98M) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($3.21M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($668.7K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($27.9K) | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $82.2K | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | ($74.0K) | Apr 10, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Jun 30, 2016 | $5.1K | May 15, 2017 |
| FY2016 | Jun 30, 2015 | $0 | May 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.84M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($2.93M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($1.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.77M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($3.15M) | Apr 15, 2022 |
| FY2022 | Dec 31, 2020 | ($3.15M) | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | ($1.24M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($356.6K) | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | ($335.6K) | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | ($267.8K) | Apr 10, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.0K | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $151.6K | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $220.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $112.1K | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $153.2K | Apr 15, 2022 |
| FY2022 | Dec 31, 2020 | $153.2K | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | $32.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $426 | Apr 15, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 10, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.09M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $79.01M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $22.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.55M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.06M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $5.95M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.60M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.39M | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $2.44M | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | $1.56M | Apr 10, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.81M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $67.11M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $14.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.71M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.64M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $8.35M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.37M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $3.99M | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $1.94M | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | $1.38M | Apr 10, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.28M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $11.90M | Apr 6, 2026 |
| FY2025 | Dec 31, 2023 | $8.05M | Apr 6, 2026 |
| FY2024 | Dec 31, 2022 | $6.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $7.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($1.39M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | ($4.87M) | Apr 15, 2022 |
| FY2019 | Dec 31, 2018 | ($1.60M) | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | $501.1K | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | $185.3K | Apr 10, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.79M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $6.75M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $5.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.17M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.54M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.54M | Apr 15, 2022 |
| FY2021 | Apr 15, 2020 | $81.8K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.46M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 15, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.28M) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | ($32.70M) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | ($26.08M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($24.50M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.54M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($14.70M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($8.13M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.67M) | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | ($492.4K) | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | ($563.2K) | Apr 10, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.51M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $1.36M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.33M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.33M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $753.3K | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $270.5K | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $4.6K | Apr 15, 2021 |
| FY2018 | Jun 30, 2018 | $25.4K | Nov 14, 2018 |
| FY2019 | Dec 31, 2017 | $23.3K | Apr 15, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.05M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.46M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | $364.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $202.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $434.7K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.60M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $267.7K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $194.6K | Apr 15, 2020 |
| FY2018 | Dec 31, 2017 | $228.0K | Apr 10, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Apr 14, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.67M | Apr 6, 2026 |
| FY2025 | Dec 31, 2024 | 2.54M | Apr 6, 2026 |
| FY2024 | Dec 31, 2023 | 172.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 161.60M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 147.48M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 118.13M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 18.01M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 15.02M | Apr 15, 2020 |
| FY2018 | Jun 30, 2018 | 15.00M | Nov 14, 2018 |
| FY2018 | Dec 31, 2017 | 11.09M | Apr 10, 2019 |